

## **ARCA develops investigational beta blocker**

Boulder County Business Report

By Business Report Staff

September 22, 2008

ARCA biopharma Inc. developed an investigational drug that could reduce hospitalization and death among heart failure patients according to a recent study, the company announced Monday.

...

To determine whether or not a patient will positively respond to bucindolol, doctors first conduct a genetic test.

"While currently available beta blockers are a mainstay in medicine, it is difficult for physicians to predict which patients will respond to which therapy," said Michael Bristow, ARCA's founder and chief science and medical officer. "The time is coming when we can realize the benefits of personalized medicine in cardiovascular disease."

For complete article, click [here](http://www.bcbcr.com/article.asp?id=96168) [hotlink to <http://www.bcbcr.com/article.asp?id=96168>]